[HTML][HTML] T-cell therapy using interleukin-21–primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell …

AG Chapuis, IM Roberts, JA Thompson… - Journal of Clinical …, 2016 - ncbi.nlm.nih.gov
AG Chapuis, IM Roberts, JA Thompson, KA Margolin, S Bhatia, SM Lee, HL Sloan, IP Lai…
Journal of Clinical Oncology, 2016ncbi.nlm.nih.gov
Purpose Peripheral blood–derived antigen-specific cytotoxic T cells (CTLs) provide a readily
available source of effector cells that can be administered with minimal toxicity in an
outpatient setting. In metastatic melanoma, this approach results in measurable albeit
modest clinical responses in patients resistant to conventional therapy. We reasoned that
concurrent cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) checkpoint blockade might
enhance the antitumor activity of adoptively transferred CTLs.
Abstract
Purpose
Peripheral blood–derived antigen-specific cytotoxic T cells (CTLs) provide a readily available source of effector cells that can be administered with minimal toxicity in an outpatient setting. In metastatic melanoma, this approach results in measurable albeit modest clinical responses in patients resistant to conventional therapy. We reasoned that concurrent cytotoxic T-cell lymphocyte antigen-4 (CTLA-4) checkpoint blockade might enhance the antitumor activity of adoptively transferred CTLs.
ncbi.nlm.nih.gov